CTOs on the Move

Cyrano Therapeutics

www.cyranotherapeutics.com

 
The Cyrano team has developed a unique, proprietary intranasal product to restore function in patients with a chronic loss of taste and smell. This is a condition affecting at least 14 million people in the US and a similar number in Europe, having a significant impact on safety, quality of life and well-being.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Cyrano Therapeutics raised $12.8M on 12/10/2020

Similar Companies

Surefire Medical

The pioneering team at Surefire Medical is inventing the future for cancer care. We develop advanced liver cancer infusion systems that overcome the limitations of traditional tools and delivery methods. Clinical discoveries paired with new, precise technology arm physicians to harness infusion pressure and work with the body’s natural flow, targeting tumors with superior accuracy, control and protection. Our founders, a biomedical engineer and an Interventional Radiologist, established Surefire Medical to revolutionize cancer treatment. Our inventive device technology is designed by and for the IR community by a Colorado-based team of physicians, engineers and researchers. We seek clinical discoveries and create new technologies with one goal in mind: to deliver improved outcomes for cancer patients and their families.

Ortho Technology Inc

Ortho Technology Inc is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Jems

Jems is a Orion, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aesculap

Aesculap is a Center Valley, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PAVmed

PAVmed (NASDAQ: PAVM) is a highly-differentiated, multi-product medical device company employing a unique and proven business model designed to advance products from concept to commercialization much more rapidly and with significantly less capital than the typical medical device company. This model enables us to pursue an expanding pipeline strategy with a view to enhancing and accelerating value creation.